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Abstract 
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Background 
Chemotherapy and radiotherapy combination is standard of care in the treatment of inoperable stage 
III non-small cell lung cancer (NSCLC). We aimed at assessing whether the addition of concurrent 
taxane-based chemotherapy to thoracic irradiation following platinum-taxane-based induction 
chemotherapy was able to improve treatment outcome. 
Patients and methods 
Patients with inoperable stage III NSCLC were randomized in PITCAP trial to receive 2 cycles of 
induction chemotherapy with cisplatin or carboplatin and paclitaxel followed by 60-61.2 Gy 
continuous thoracic irradiation (control arm) or by same radiotherapy with concomitant weekly 
paclitaxel (experimental arm). Furthermore, we performed a systematic review and a literature-
based meta-analysis including all studies in which, after induction chemotherapy, a concurrent 
taxane-based chemo-radiotherapy program was compared to thoracic radiotherapy alone in locally 
advanced NSCLC. Primary measure of outcome in the meta-analysis was probability of 1-year 
survival.  
Results 
In the PITCAP trial, at the time of the second planned interim analysis, when 151 patients were 
randomized, accrual was terminated, due to slow recruitment. With a median follow-up of 6.1 years, 
median survival was 13.2 vs. 15.1 months, with a 3-year survival rate of 19.5% vs. 21.2% in the 
control and experimental arm, respectively (HR: 0.97; 95%CI 0.69-1.36; p = 0.845). No significant 
difference was observed in overall response rate (54% vs 52%) and progression-free survival 
(median 6.7 vs 9.2 months, in the control and experimental arm, respectively). Treatment toxicity 
was manageable in both arms (grade 3-4 esophagitis was 4.3% vs 10% in the control and 
experimental arm, respectively; p = 0.278). The meta-analysis, including 5 trials (n = 866), 
confirmed the lack of a meaningful effect on 1-year overall survival (OR: 1.17; 95%CI 0.75-1.82) 
of single agent taxane added concurrently to thoracic radiotherapy.  
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Conclusions 
The results of PITCAP trial along with those of the meta-analysis do not support a clinically 
meaningful benefit with the addition of single agent taxane given concurrently to thoracic 
irradiation after platinum-based chemotherapy induction in locally advanced inoperable NSCLC. 
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Introduction 
Lung cancer still represents the leading cause of cancer death in developed countries [1]. Non-small 
cell lung cancer (NSCLC) accounts for approximately 80-85% of all lung cancer cases and is 
characterized by advanced inoperable stage at diagnosis in most patients and by a very low cure-
rate. While the standard of care of metastatic disease is represented by systemic therapy alone, 
optimal management of locally advanced inoperable disease, representing 20-30% of all NSCLC 
cases, entails the combined use of chemotherapy and radiotherapy. Chemo-radiotherapy 
combination may lead to a 5-year overall survival rate of approximately 20-30% [2].  
In the context of multidisciplinary treatment, according to the results of several randomized studies 
and meta-analyses, timing of radiotherapy is important, given that early administration of 
radiotherapy concurrently with chemotherapy appears to be associated with better outcome, albeit 
producing increased local and systemic toxicity [3]. On the contrary, when using concurrent chemo-
radiation, evidence has shown no benefit by adding induction or consolidation chemotherapy [4, 5].  
In the contest of combined chemo-radiation treatment of NSCLC, platinum-based regimens, such as 
carboplatin-paclitaxel, cisplatin-etoposide or cisplatin-vinorelbine are recommended [6]. 
Concerning dose and schedule of radiotherapy, doses of 60-65 Gy delivered high-energy linear 
accelerators in 30-32 daily fractions are regarded as the standard of care [6]; increased dose of 
radiation and varied fractionation such as hyper or hypo-fractionation has not led to significantly 
improved results in overall survival [2,7,8]. 
Despite the evidence that concurrent chemo-radiation is superior in terms of survival outcome 
compared to sequential treatment [3], its use in real world clinical practice is limited by several 
factors including increased toxicity, too large volume disease to irradiate, advanced age, poor 
performance status (PS), presence of comorbidities and, in some cases, radiotherapy waiting lists. 
For these reasons, according to recent surveys, particularly in Europe [9, 10], but also in US [11], in 
clinical practice sequential chemo-radiotherapy protocols are still used in a large proportion of 
patients with locally advanced inoperable NSCLC. In this context, little evidence has been produced 
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about the potential benefit of adding chemotherapy concurrently to thoracic irradiation delivered 
after induction chemotherapy [12].  
Given this background, our PITCAP (Progetto Interdisciplinare Terapia Carcinoma Polmonare) 
study was designed to verify whether the addition of a low-toxicity profile chemotherapy regimen 
such as weekly paclitaxel, given concurrently with thoracic irradiation after platinum-based 
induction chemotherapy was able to improve clinical outcome as compared to standard sequential 
chemo-radiotherapy in locally advanced inoperable NSCLC. Since we were aware of other few 
studies [13-17] with similar design and objective, we also performed a systematic review and a 
literature-based meta-analysis (TROCODILE meta-analysis, Taxane-based chemo-RadiOtherapy 
COmpared with raDIotherapy aLonE after induction chemotherapy in locally advanced Non-Small-
Cell Lung Cancer) including all randomized trials addressing the same scientific question. 
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Patients and methods 
Study design 
Eligible patients were required to have: cytologically or histologically-confirmed newly-diagnosed 
NSCLC; inoperable clinical stage III disease with absence of pleural or pericardial effusion, 
supraclavicular node metastasis or esophageal or cardiac or spinal cord infiltration; age ≤ 70 years; 
ECOG performance status (PS) ≤ 1; and FEV1 (Forced Expiratory Volume one second) ≥ 1L; 
normal hepatic, renal and cardiac functions; absence of weight loss ≥ 10% in the previous 6 
months; no prior chemotherapy and/or radiotherapy. Treatment in the control arm consisted of 2 
cycles of paclitaxel 200 mg/m
2
 combined with either carboplatin AUC 6 or cisplatin 80 mg/m
2
 (at 
investigator choice) day 1 every 3 weeks followed by continuous thoracic irradiation either 60 
Gy/30 fractions (200 cGy/fraction 5 days/week for 6 weeks, 22 fractions plus 8 boost fractions) or 
61.2 Gy/34 fractions (180 cGy/fraction 5 days/week for 7 weeks, 25 fractions plus 9 boost 
fractions) (at investigator choice) delivered by high energy (4 MeV or higher) linear accelerator 
within 21-35 days from the 2
nd
 chemotherapy induction course to the GTV (gross tumor volume) 
plus 2 cm margin as assessed by baseline CT scan. Experimental arm consisted of identical 
induction chemotherapy and thoracic irradiation with the addition of paclitaxel 60 mg/m
2
 weekly 
for 6-7 weeks concurrently to thoracic irradiation. Patients were assessed at baseline with total body 
CT scan, pulmonary function tests and complete blood count and chemistry. 
The study was conducted under the auspices of the Italian cooperative group FONICAP (Forza 
Operativa Nazionale Carcinoma Polmonare) and approved by Ethical Committee/Institutional 
Review Boards of all participating Institutions 
 
Statistical considerations 
PITCAP trial 
The primary objective of this randomized phase III trial was to assess the efficacy of adding weekly 
paclitaxel to standard thoracic irradiation after platinum-paclitaxel induction chemotherapy. Primary 
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end-point was overall survival (calculated as the time between randomization and death from any 
cause, or date of last follow-up visit for alive patients), while secondary end-points included 
progression-free survival (calculated as the time from randomization to the date of progressive 
disease or death, or date of last follow-up visit for patients alive without progression),  response rate 
(measured according to WHO criteria) and toxicity (measured according to WHO/ECOG/RTOG 
criteria). 
Planned accrual was 300 patients, in order to detect at least 30% mortality reduction with the 
addition of concurrent chemotherapy in the experimental arm (α = 5%; β = 20[M1]%). The 
enrollment, according to the study protocol, was stopped after the inclusion of 151 patients due to 
the low observed accrual rate.[M2] Patients were centrally assigned in a 1:1 ratio to receive 
concurrent chemo-radiotherapy (experimental group) or radiotherapy alone (control group) after 
induction treatment. Randomization was stratified by clinical site. 
The median period of follow-up was calculated for the entire study cohort according to the reverse 
Kaplan–Meier method. Distributions of time-to-event variables were estimated with the use of the 
Kaplan–Meier product-limit method. The log-rank test was used as the primary analysis for 
comparison of treatment groups. Cox proportional-hazards modeling was also performed as 
supportive analyses, with xxx as covariates. The objective response rate and the incidence of 
adverse events in the two groups were compared with the use of the chi-square test for 
heterogeneity or with Fisher’s exact test when appropriate. All statistical tests were two-sided, and P 
values of 0.05 or less were considered to indicate statistical significance. 
TROCODILE Meta-analysis 
Data from all published and unpublished randomized trials in locally advanced (stage IIIA-B) 
NSCLC in which, after induction chemotherapy, a concurrent taxane-based chemo-radiotherapy 
strategy vs radiotherapy alone were compared were sought. After the same induction chemotherapy 
in both arms, the control and experimental arms had to differ only by presence or not of 
concomitant taxanes-containing chemotherapy (paclitaxel or docetaxel). Therefore, all randomized 
 8 
trials with the following design were considered: induction chemotherapy (same drugs and schedule 
in the control and experimental arms) followed by radiotherapy (same fractionation and dosage in 
the control and experimental arms) vs induction chemotherapy followed by paclitaxel or docetaxel 
combined with radiotherapy. Studies testing the administration of taxane as single-agent or 
combined with other agents (e.g. weekly carboplatin plus paclitaxel) were both eligible.  
Eligible trials were identified by regular computer-aided searches, through literature databases 
(MEDLINE, CANCERLIT), examining reference lists of published trials, review articles, searching 
ASCO, ESMO and WCLC meeting abstracts from 2009 to 2014, and consulting trials registers (US 
National Cancer Institute Physicians Data Query Clinical Protocol). For databases research the 
following strategies were used: “Chemotherapy [MeSH] AND Radiotherapy [MeSH] AND 
Carcinoma, Non-small-cell lung/drug therapy [MeSH] AND Clinical trial [pt]” and “Chemotherapy 
AND Radiotherapy AND Locally Advanced Non-small cell lung cancer” 
Primary measure of outcome for the meta-analysis was the odds ratio (OR) of being alive 1 year 
after randomization for experimental arm (radiotherapy plus taxane) versus control arm 
(radiotherapy alone). We chose this measure at a fixed time point (1-year) because hazard ratio was 
not available for all the publications. The proportion of patients alive 1-year after randomization 
was extracted from the publication, when available, calculated from the Kaplan-Meier curves or 
obtained directly from the authors. After data were abstracted, meta-analysis was performed using 
RevMan 5.1 software, developed by the Cochrane Collaboration. A random-effects model was 
applied. Statistical heterogeneity between studies was examined using the 2 test and the I2 statistic.  
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Results 
PITCAP Trial 
Due to slow recruitment, accrual was terminated early, at the time of the second planned interim 
analysis, when 152 patients had been randomized from February 2000 to November 2004 at 26 
Italian centres. Patient disposition is shown in Figure 1. One patient was excluded from the 
intention-to-treat because it was randomized twice by mistake. Patients characteristics of the 151 
patients eligible for analysis are reported in Table 1. Patients characteristics were well balanced 
between the two arms. In summary, overall median age was 61 years; most patients were males 
(91%), 68% had stage IIIB, 60% had PS 0, 42% had squamous histology. 
Overall, 44% of patients received cisplatin and 56% carboplatin in combination with paclitaxel in 
the induction chemotherapy program, with no difference between the two study arms. Induction 
chemotherapy was well tolerated, with 5.3% leukopenia and 20% neutropenia as the most frequent 
grade 3-4 side effects. One-hundred forty-four patients completed the 2 planned courses and a total 
of 294 courses were delivered, with only 1.7% dose-reduction and 4.2% treatment delays of cycle 2. 
Seventeen and 14 patients, respectively, did not proceed to consolidation radiotherapy, with or 
without weekly paclitaxel, due to either disease progression or clinical deterioration. Response rate 
to induction? 
Among the 119 patients who started irradiation treatment, radiotherapy was completed as per 
protocol in in the majority (??%) of patients, with a median total RT dose of 60 Gy (delivered in 6 
weeks in 53% of patients and 7 weeks in the remaining) in both arm. Nearly 80% of patients in 
experimental arm completed concurrent weekly paclitaxel as per protocol. Treatment toxicity was 
manageable in both arms (grade 3-4 esophagitis 4.3 vs 10%; p = 0.278); one toxic death was 
recorded in the concurrent chemoradiation arm. Altre tossicità? Site of progression according 
treatment arm? 
Overall response rate and median progression-free survival did not differ according to treatment 
(54% vs 52% and 6.7 vs 9.2 months, in the control and experimental arm, respectively) (Table 2). 
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With a median follow-up of 6.1 years, median survival was 13.2 vs 15.1 months with a 3-year 
survival rate of 19.5% vs 21.2% in the control and experimental arm, respectively (HR: 0.97; 
95%CI 0.69-1.36; p = 0.845) (Figure 2). Futility? 
Meta-analysis 
Five further trials were identified [13-17]; one of these was not considered in the meta-analysis 
because the sequential chemo-radiotherapy arm was stopped early after 19 patients and its results 
were not reported in the final publication [17]. The remaining 4 trials and the present study were 
divided in two sub-groups according to the timing of randomization: after induction in three trials 
[13-15] and before induction in two trials [16 and PITCAP trial]. 
The meta-analysis showed no significant difference in the chance of being alive after 1 year 
between patients assigned to chemo-radiotherapy and patients assigned to radiotherapy arm. In 
detail, as shown in Figure 3, the proportion of patients alive after 1 year was 57.4% in both arms 
(OR: 1.00; 95%CI: 0.76-1.31; p = 1.00), without statistical heterogeneity among the 5 trials (I
2 
= 
0%; p = 0.85). As for subgroup analysis according to the timing of randomization, no significant 
difference was observed in the three trials performing randomization after induction (OR: 1.02; 
95%CI 0.72-1.43; p = 0.93), nor in the two trials performing randomization before induction (OR: 
0.97; 95%CI 0.62-1.52; p = 0.90).  
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Discussion 
According to international guidelines [6, 18-20], concurrent platinum-based chemotherapy and 
thoracic irradiation is the recommended treatment for locally advanced inoperable NSCLC. This 
recommendation is based on the results of a series of randomized studies and meta-analyses 
demonstrating the superiority of concurrent chemo-radiation over radiotherapy alone [21, 22] and 
over sequential chemo-radiation [23-26] at the cost, however, of an increased toxicity [3]. On the 
contrary, induction chemotherapy preceding concurrent chemo-radiation [4] and consolidation 
chemotherapy after chemo-radiation [5], although still commonly used in clinical practice, have not 
been proved to add any efficacy in terms of long-term survival outcome to concurrent chemo-
radiation alone.  
However, despite the scientific evidence of its superior efficacy, in real world clinical practice 
concurrent chemo-radiotherapy is not applied to the majority of patients with locally advanced 
inoperable NSCLC. While in US, pattern of care surveys report the use of concurrent chemo-
radiation in approximately ¾ of patients, similar studies in EU report lower use of concurrent 
chemoradiotherapy strategy. For example, De Ruysscher et al reported the results of a population-
based study conducted in the Netherlands in which less than 50% of patients were treated with 
concurrent chemoradiation [9]. In Italy, the RIGHT3 survey showed little adherence to Italian 
Association of Medical Oncology Guidelines recommending concurrent chemo-radiation for stage 
III NSCLC [10].  
The reasons of this discrepancy between scientific societies recommendation and real world clinical 
practice are manifold. First, eligibility for concurrent chemo-radiation is scanty due to inadequate 
location and volume of the tumor, advanced age, poor PS and presence of cardiovascular and 
respiratory co-morbidities. Second, physicians and patients are often worried about increased 
toxicity of concurrent chemo-radiation which may seem not justified in view of the little benefit in 
terms of increased cure rate as compared to other forms of less toxic integration of chemotherapy 
and radiation. Finally, in several areas of the world, busy radiotherapy departments with long 
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waiting lists and cumbersome treatment planning do not allow to start thoracic irradiation as early 
as chemotherapy. For all these considerations, when we planned the PITCAP trial, clinical practice 
for the treatment of locally advanced NSCLC in Italy was largely dominated by the use of 
sequential chemo-radiation approaches. In this contest, being aware of the data supporting the 
superiority of concurrent chemo-radiation, we aimed at assessing whether the addition concurrently 
to thoracic irradiation of a feasible and highly tolerable chemotherapy, such as weekly paclitaxel, 
could improve the outcome without worsening the feasibility of this chemo-radiation regimen. 
Unfortunately, the accrual in the PITCAP trial was much lower than expected and the study had to 
be terminated earlier when half of the expected sample size was enrolled. Slow accrual is, 
unfortunately, a common theme in clinical trials of combined treatment of locally advanced NSCLC 
due to the complexity of the multidisciplinary approach, to the strict eligibility criteria and to stage 
migration with the increased use of PET scanning and brain CT/MRI in clinical staging. 
Despite the limitation of a reduced sample size and of early accrual interruption, the results of our 
study point  to the conclusion that weekly paclitaxel given concurrently to thoracic irradiation after 
platinum-paclitaxel induction chemotherapy, although feasible and very well tolerated, does not 
have a clinically meaningful effect on long-term survival outcome. 
In the literature we could identify other 4 studies with similar design [13-16], 3 of which came to 
similar conclusions [14-16] (Table 3). Belani et al reported the results of US LAMP 3-arm trial 
including 276 stage III NSCLC patients testing two carboplatin-paclitaxel induction courses 
followed by standard thoracic irradiation with or without concurrent weekly carboplatin-paclitaxel, 
along with a third regimen consisting of the same concurrent chemo-radiotherapy program followed 
by 2 carboplatin-paclitaxel courses [16]. Median survival and 3-year survival rates were 13.0, 12.7, 
and 16.3 months and 17, 15 and 17%, respectively. Although the authors concluded that concurrent 
chemo-radiotherapy followed by consolidation seemed to produce best outcomes, the study was 
formally non comparative, and no solid conclusion could be derived about the efficacy of the 
addition of chemotherapy to thoracic irradiation following induction chemotherapy. Scagliotti et al 
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conducted an European 2-arm trial in 108 stage III NSCLC patients comparing cisplatin-docetaxel 
induction chemotherapy followed by standard thoracic irradiation alone or combined with 
concurrent weekly docetaxel [14]. Survival outcomes were superimposable in the two treatment 
regimens. Huber et al enrolled 303 inoperable stage III NSCLC patients in a German randomized 
trial with identical design to the PITCAP Italian trial [13]. In this study, the addition of weekly 
paclitaxel to thoracic radiotherapy after induction carboplatin-paclitaxel led to a non-statistically 
significant numerical increase in median survival (14.1 vs 18.7 months). Brunsvig et al conducted a 
phase III trial where 249 NSCLC stage IIIA-B patients after 2 cycles of carboplatin-docetaxel were 
randomized to receive weekly docetaxel combined with radiotherapy or radiotherapy alone, 
obtaining similar survival outcome in two arms [15].  
In all these studies results, both in terms of overall outcome and of relative benefit of concurrent 
chemotherapy, were remarkably similar with median survival of about 13-15 months regardless of 
treatment arm and of the type of concurrent chemotherapy regimen used. The TROCODILE meta-
analysis included all these 5 studies. Although some heterogeneity was evident due to the different 
timing of randomization (up-front vs after induction), use of paclitaxel or docetaxel, use of 
carboplatin with paclitaxel concurrently with radiotherapy in US trial, all the available evidence 
suggests no significant benefit with the addition of taxane-based chemotherapy to thoracic 
irradiation. This result may seem in contrast with the data supporting concurrent chemo-radiation. 
However, all the evidence favoring the superiority of concurrent over sequential chemoradiation 
and radiation alone has been obtained with trials using platinum-based chemotherapy regimens 
starting concurrently with radiotherapy, without previous induction chemotherapy [21-26]. Other 
two randomized trials assessing the role of single agent carboplatin given concurrently to thoracic 
irradiation after induction chemotherapy also led to negative results [27, 28]. It might therefore be 
reasoned that induction chemotherapy could hinder the benefit of the subsequent chemotherapy 
given concurrently with radiotherapy. A plausible biological explanation of this negative effect of 
induction chemotherapy could be the early induction of chemotherapy resistance and/or the 
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recruitment of proliferating neoplastic cells as it has been shown in experimental models [29].  
Of course, differently from a meta-analysis based on individual patient data, our literature-based 
meta-analysis has some intrinsic limitations, the most relevant being the different timing of 
randomization among trials and the unfeasibility of exploratory subgroup analysis to test the 
presence of interaction among main patients’ characteristics and treatment efficacy.  
In conclusion, the results of PITCAP trial together with those of TROCODILE meta-analysis, do 
not support a clinically meaningful benefit with the addition of taxane-based chemotherapy given 
concurrently to thoracic irradiation after platinum-based chemotherapy induction in locally 
advanced inoperable NSCLC. In patients where upfront chemo-radiation, which remains the 
optimal treatment option for ideal candidates, is not feasible and induction chemotherapy followed 
by thoracic irradiation is planned, radiotherapy can be delivered alone without the addition of 
further chemotherapy. 
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Figure Legend 
Figure 1: Consort Diagram.  
Figure 2: Kaplan Meyer Survival Curves (panel A: PFS; panel B: OS). 
Figure 3: Forest Plot Meta-Analysis.  
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Appendix: Particpating Institutions 
Parma: Franciosi 4 
Perugia: Crinò  4 
Regina Elena: Francesco Cognetti , Arcangeli 4 
Cuneo: Marco Merlano Elvio Russi 3 
Torino: Fornari 3 
Lugo Ravenna: Cruciani 3 
Pisa: Conte, Cionini, Silvano 3 
Bergamo: La Bianca 3 
Brescia Frata 3 
Terni: Di Costanzo 2 
Asti: Testore 2 
Monza: Ardizzoia 1 
Ivrea: bretti 1 
Ravenna: marangolo 1 
Roma s.camillo: 1 
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